-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Frontiers in Oncology published a real-world study from the United States, mainly evaluating the long-term efficacy of first-line pembrolizumab (pembrolizumab) monotherapy in patients with advanced NSCLC
with PD-L1 ≥ 50% .
with PD-L1 ≥ 50% .
NSCLC
The study included two cohorts of patients: the electronic medical record cohort (EHR cohort) and the manual review cohort (spotlight cohort), and assessed overall survival (OS) in the two cohorts, and real-world progression-free survival (rwPFS) in the spotlight cohort and real-world Tumor Response (rwTR)
.
.
The EHR cohort included 566 patients (298 [53%] men); whereas the spotlight cohort included 228 patients (105 [46%] men); the median age of patients in both groups was 71 years
.
.
The median follow-up time in the EHR and spotlight cohorts was 35.
1 months (range 12.
0-52.
7) and 38.
4 months (range 33.
1-44.
9), respectively
.
The median OS was 19.
The median follow-up time in the EHR and spotlight cohorts was 35.
Of the 182 (32%) patients in the EHR cohort who received second-line systemic therapy, most commonly platinum-based chemotherapy or immunotherapy (ICI monotherapy or ICI-chemotherapy), 63 (35%) patients received third-line therapy treatment, and 16/63 (25%) patients received fourth-line therapy
.
In the spotlight cohort, 87 (38%) patients received second-line therapy, of which 26 (30%) received third-line therapy; 7 were fourth-line therapy, and 3 were fifth-line therapy
Of the 182 (32%) patients in the EHR cohort who received second-line systemic therapy, most commonly platinum-based chemotherapy or immunotherapy (ICI monotherapy or ICI-chemotherapy), 63 (35%) patients received third-line therapy treatment, and 16/63 (25%) patients received fourth-line therapy
For the spotlight cohort, the median rwPFS was 7.
3 months (95% CI, 5.
7 9.
2)
.
3 months (95% CI, 5.
7 9.
2)
.
For the spotlight cohort, the median rwPFS was 7.
In the spotlight cohort, a total of 17 patients (7%) had an rwTR assessment of CR, 71 patients (31%) had a PR assessment of PR, and the rwTRR was 38.
6% (95% CI, 32.
2-45.
2) for a total of 122 patients ( 54%) disease control (CR + PR + stable disease)
.
6% (95% CI, 32.
2-45.
2) for a total of 122 patients ( 54%) disease control (CR + PR + stable disease)
.
In the spotlight cohort, a total of 17 patients (7%) had an rwTR assessment of CR, 71 patients (31%) had a PR assessment of PR, and the rwTRR was 38.
For 151 of 228 patients (66%) who discontinued pembrolizumab, the most common reasons were disease progression (70 [46%]) and treatment-related adverse reactions (35 [23%])
.
No serious adverse reactions were found
For 151 of 228 patients (66%) who discontinued pembrolizumab, the most common reasons were disease progression (70 [46%]) and treatment-related adverse reactions (35 [23%])
In conclusion, the study shows that for patients with advanced NSCLC with PD-L1≧50%, the real-world efficacy of first-line pembrolizumab (pembrolizumab) monotherapy is consistent with clinical studies, which supports the application of this regimen
.
.
Studies have shown that for patients with advanced NSCLC with PD-L1≧50%, the real-world efficacy of first-line pembrolizumab (pembrolizumab) monotherapy is consistent with clinical studies, supporting the application of this regimen
.
Studies have shown that for patients with advanced NSCLC with PD-L1≧50%, the real-world efficacy of first-line pembrolizumab (pembrolizumab) monotherapy is consistent with clinical studies, supporting the application of this regimen
.
Original source:
Original source:Velcheti V, Hu X, Yang L, Pietanza MC and Burke T (2022) Long-Term RealWorld Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Front .
Oncol.
12:834761.
doi: 10.
3389/fonc.
2022.
834761
Front .
Oncol.
12:834761.
doi: 10.
3389/fonc.
2022.
834761
leave a message here